Annovis Bio Targets Multiple Brain Proteins to Fight Alzheimer's With New Drug
Annovis Bio's buntanetap targets five neurotoxic proteins at once, challenging Alzheimer's single-protein dogma in a pivotal Phase 3 trial.
Summary
Annovis Bio is developing buntanetap, an oral once-daily drug designed to tackle Alzheimer's disease by blocking multiple harmful proteins — including amyloid beta, tau, and alpha-synuclein — simultaneously. Most Alzheimer's drugs have focused on just one protein, particularly amyloid beta, with limited success. Annovis argues the disease is driven by several aggregating proteins at once, and that targeting all of them together may produce better outcomes. The company reports encouraging biomarker data and meaningful clinical benefits from early trials, and is now running a pivotal Phase 3 study. CEO Maria Maccecchini will present this multi-protein strategy at Fierce Biotech Week 2026 in Boston on May 13.
Detailed Summary
Alzheimer's disease remains one of the most treatment-resistant conditions in medicine, and a key reason may be that the field has spent decades chasing a single culprit. Most approved and experimental therapies have focused on removing or blocking amyloid beta, a protein that clumps in the brain. Despite some recent approvals, results have been modest and side effects significant. Annovis Bio believes this single-protein approach is fundamentally incomplete.
The company's investigational drug buntanetap works as a translational inhibitor — meaning it interferes with the production of multiple neurotoxic proteins at the source. Its targets include APP, amyloid beta, tau, alpha-synuclein, and TDP-43. Each of these proteins has been independently linked to neurodegeneration. Tau tangles are a hallmark of Alzheimer's pathology, alpha-synuclein is central to Parkinson's disease, and TDP-43 is implicated in ALS and frontotemporal dementia. Blocking all of them simultaneously is an ambitious and scientifically distinctive approach.
Annovis reports that earlier clinical stages have shown meaningful improvements in patient outcomes alongside supportive biomarker data. The drug is now advancing into a pivotal Phase 3 trial, the final stage before potential regulatory review. CEO Maria Maccecchini, a neuroscientist and longtime Alzheimer's researcher, will present the scientific rationale and clinical evidence at Fierce Biotech Week 2026 in Boston.
For the longevity-focused community, this matters beyond Alzheimer's specifically. Protein aggregation is a core mechanism of brain aging, and drugs that can reduce the burden of multiple toxic proteins could have broader neuroprotective implications. If buntanetap proves effective, it may reframe how we think about late-life cognitive decline.
However, Phase 3 success is far from guaranteed. Many promising Alzheimer's drugs have failed at this stage. The evidence base cited here is preliminary, and peer-reviewed Phase 3 results have not yet been published.
Key Findings
- Buntanetap targets five neurotoxic proteins — APP, amyloid beta, tau, alpha-synuclein, TDP-43 — in one oral daily drug.
- Annovis argues Alzheimer's is a multi-protein disease, challenging the field's long-standing single-amyloid focus.
- Early clinical data reportedly shows meaningful patient benefits and encouraging biomarker improvements.
- Buntanetap is now in a pivotal Phase 3 trial, the final stage before potential regulatory submission.
- Multi-protein inhibition could have broader neuroprotective relevance beyond Alzheimer's to Parkinson's and ALS.
Methodology
This is a news report summarizing a corporate announcement and upcoming conference presentation. The source, Longevity.Technology, is a credible longevity-focused publication. Evidence cited is company-reported and not yet independently peer-reviewed.
Study Limitations
All efficacy and biomarker claims originate from the company and have not been independently verified or published in peer-reviewed journals. Phase 3 trials frequently fail even after promising earlier phases. Readers should await published trial data before drawing conclusions about clinical utility.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.